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Phenotypic expression of hereditary hemochromatosis(HH) related to the hemochromatosis gene HFE isgenerally defined by biochemical measures of iron
overload coupled with either nonspecific or organ-specific
clinical features. However, the clinical disease burden of
HFE-related HH is difficult to ascertain due to interindi-
vidual variation of symptoms and signs, as well as differences
in populations studied.1 Although C282Y homozygotes are
genetically predisposed to events that may culminate in se-
vere damage to susceptible organs, there is inadequate
knowledge to predict the degree of phenotypic expression in
individuals.1,2 HH is therefore more common when defined
by genotype than by biochemical evidence of raised serum
iron indices, which in turn is more common than docu-
mented hepatic iron overload; least common is symptomatic
organ damage.2 Although the potential for liver disease with
iron loading in C282Y homozygotes is well accepted, the risk
of other organ involvement is more controversial. The asso-
ciation of other HFE variants with organ damage is even
more contentious.
Prior to the HFE-gene era, HH was defined based on
clinical phenotypic expression and familial inheritance of
the disorder. Clinical expression generally relied on detec-
tion of iron overload (raised iron indices and/or hepatic
iron overload on liver biopsy) plus clinical features of iron
overload, including cirrhosis, bronze pigmentation of the
skin and diabetes mellitus (the so-called bronze diabetes
phenotype), hepatocellular cancer, cardiomyopathy, de-
structive arthritis, and hypogonadism.3 The bronze dia-
betes phenotype is now relatively rare. With the advent of
HFE gene mutation testing, it has been possible to diag-
nose “potential hemochromatosis”, that is, individuals at
increased risk of clinically significant iron loading based
on the finding of C282Y homozygosity. Although this has
enabled diagnosis of preclinical and early HH, not all
homozygotes will develop significant iron overload or dis-
ease.
Many clinical symptoms and disorders have been at-
tributed to HH but the degree of penetrance of these has
been controversial. Several large cross-sectional cohort
studies from North America, Europe, Australia, and the
United Kingdom have reported a variable clinical pen-
etrance of HH despite its relatively high genotypic prev-
alence and biochemical penetrance4-7 A recent
comprehensive review of penetrance of HH described he-
patic iron overload, hepatic fibrosis, and cirrhosis in 38%,
25%, and 6%, respectively, of all C282Y homozygotes
identified from population screening.2 It was extrapolated
that if all unevaluated homozygotes were unaffected, this
would correspond to adjusted “minimal estimates” of
24%, 6%, and 1.4%, respectively. Homozygosity for the
HFE C282Y variant has been estimated to have a pen-
etrance of between 1.3% and 2.1% for hepatocellular
carcinoma.8 Many symptoms and signs attributable to
iron overload from HH are nonspecific, such as fatigue,
abdominal pain, hepatomegaly, and arthralgia. Further-
more, features of advanced HH such as cirrhosis, diabetes,
infertility, and arthritis are uncommon below the age of
40.9,10 Figure 1 illustrates the relative levels of penetrance
of biochemical and clinical features of HH.
In this issue of HEPATOLOGY, Ellervik and colleagues11
systematically explore the relationship between homozy-
gous, heterozygous, and compound heterozygous HFE vari-
ants (C282Y/C282Y, H63D/H63D, C282Y/wild type,
H63D/wild type, and C282Y/H63D) relative to the wild
type for the risk of various disease endpoints. By conducting
meta-analyses including 202 predominantly case-controlled
studies, the authors have concluded that the presence of HFE
variants alone does not confer an increased risk of type 2
diabetes mellitus, coronary artery disease, arthritis, stroke,
and venous disease. Subgroup analysis did, however, detect
an increased risk of liver disease (odds ratio  3.9) and type
2 diabetes (odds ratio 3.4) in clinically detected (as opposed
to screening detected) C282Y homozygotes of Northern Eu-
ropean origin. Disease association was strongest for the pres-
ence of any HFE variant with porphyria cutanea tarda (odds
ratio 1.9-48). H63D homozygosity was associated with an
increased risk of amyotrophic lateral sclerosis (odds ratio 
3.9).
Complications of HH such as hepatic fibrosis and cir-
rhosis, and patient prognosis in the presence of these,
depend on the amount and duration of iron excess.12,13
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Significant hepatic fibrosis and cirrhosis are more likely in
subjects with a hepatic iron content of greater than 233
mmol/g14,15 or a product of hepatic iron concentration
multiplied by age of greater than 9000.13 The latter pa-
rameter introduces the concept that it is not only the
amount of iron responsible for liver injury but also the
time of exposure to the iron as reflected by age. Subjects
who consume excessive alcohol may develop hepatic fi-
brosis and cirrhosis at lower hepatic iron concentrations
than those who do not consume excessive alcohol.16
Specific characteristics of arthritis associated with HH
have been described.17 These include arthralgia and arthritis,
initially involving the meta-carpophalangeal joints (particu-
larly the second and third meta-carpophalangeal joints) and
later involvement of large joints such as the hips, knees, and
shoulders. An increased prevalence of HH as determined by
iron indices and liver histology was described in a study com-
paring a rheumatology clinic population with the general
population.18 The significance of HFE variants in the gen-
eral population with arthritis is, however, controversial. Pop-
ulation studies from the United States and Australia have not
detected a correlation between HFE genotypes and arthri-
tis.6,19 Likewise, a study from the United Kingdom did not
find an increase in prevalence of C282Y homozygosity in
1000 patients with inflammatory arthritis relative to a con-
trol population.20
Regarding coronary artery disease, a limited number of
studies have suggested that iron overload or the C282Y
mutation might confer an increased risk for coronary ath-
erosclerosis.21 Several other studies have, however, failed
to establish an association between HFE genotypes and
coronary artery disease.22-24 Cardiomyopathy and ar-
rhythmias are recognized sequelae of untreated HH and
are generally associated with severe hepatic iron overload
and liver disease.13,25
The traditional bronze diabetes phenotype of HH
commonly found in early reports of the disorder is now
rare. The relationship between HFE variants and type 2
diabetes is contentious. Diabetes and impaired glucose
tolerance are recognized associations of advanced liver
disease of any etiology, including HH. Organ damage
affecting the liver and pancreas in advanced HH is asso-
ciated with insulin resistance, pancreatic beta cell dys-
function, and diabetes. Reports suggesting a high
prevalence of disordered glucose homeostasis in HH are
common.26,27 However, several studies have now demon-
strated a low prevalence of diabetes mellitus among
C282Y homozygotes.5,6 The hemochromatosis and iron
overload screening (HEIRS) study of 97,470 people resi-
dent in North America did not establish a significant as-
sociation between self-reported diabetes and HFE
variants.28 Halsall and colleagues reported similar results
from a population study and meta-analysis.29 Diabetes
alone is a poor predictor of HH, and routine HH screen-
ing of patients with type 2 diabetes is not recommend-
ed.30
The main limitation of the current study is that it is
only relevant to individuals clinically diagnosed with HH
and cannot be extrapolated to C282Y homozygotes who
have not been clinically ascertained. As progress is made
toward achieving a better understanding of the genotype-
phenotype association with HFE variants, it will become
clearer whether a role for HFE genotyping of certain pop-
ulations will emerge. Elucidation of the true clinical dis-
ease burden of C282Y homozygosity remains a key
unanswered question and could only be addressed in large
prospective population-based studies. The proportionate
contribution of genes versus environment toward pheno-
typic expression of HH needs to be explored in greater
detail. That notwithstanding, the article by Ellervik and
colleagues provides further insights into disease manifes-
tations of clinically expressed C282Y homozygosity.
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Fig. 1. Proportion of patients with C282Y homozygous HH who de-
velop iron overload and liver disease.2,8
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